CoronaryAtlas logo
CoronaryAtlas
HDL cholesterol
Pathway / Lipid retention & oxidation

HDL cholesterol

lipoprotein

HDL removes cholesterol and phospholipid hydroperoxides from lesions, opposing atherosclerotic lipid accumulation.

Pathway placement
Cascade stepLipid retention & oxidation
Confidencehigh
RationaleCardioprotective lipoprotein opposing LDL atherogenesis.
Druggability
Not assessed (no mapped human gene target).

Type I vs non-Type I discrimination

ScoresIndeterminate
R — rupture / Type-I
33
C — non-Type-I
33
A — assay feasibility
84
E — evidence strength
57
T1DI (composite)
24
Specificity differential (R−C)-0.3
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationmag 1
2anemia / acute blood lossn/a
2hypovolemia / dehydrationn/a
2tachyarrhythmiamag 1
2hypoxemia / respiratory failuremag 1
2hypertensive emergencyn/a
2high-demand / peri-operative stressn/a
3sudden cardiac deathmag 1
4aPCI-related periproceduraln/a
4bstent thrombosismag 1
4cin-stent restenosisn/a
5CABG-relatedn/a
Coverage: 5/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 6 supporting references. See the discrimination table for all markers.

Assay & specimen

Validated clinical assay
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top)
Method / principle
Direct enzymatic (homogeneous)
Reagent / substrate
Selective detergent + cholesterol esterase/oxidase/peroxidase Trinder
Platform
Automated analyzer
Turnaround · availability
Routine · Universal

Literature evidence(16)

Clinical trials(1)